PRL and breast cancer: L-dopa was recently reported to suppress cellular growth via down-regulation of prolactin-mediated JAK2/STAT5A in breast cancer cells 50, and carbidopa was reported to be an aryl hydrocarbon receptor agonist and to suppress the growth of pancreatic cancer 51.